# Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma

> **NCT07643519** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Florida** · enrollment: 39 (estimated)

## Conditions studied

- Urothelial Carcinoma (UC)

## Interventions

- **DRUG:** enfortumab vedotin and pembrolizumab (EV/P)

## Key facts

- **NCT ID:** NCT07643519
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2029-02
- **Final completion:** 2030-10
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07643519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07643519, "Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer and Upper Tract Urothelial Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07643519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*